Pliant Therapeutics, Inc.

NasdaqGS:PLRX Stock Report

Market Cap: US$87.8m

Pliant Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Bernard Coulie

Chief executive officer

US$6.6m

Total compensation

CEO salary percentage9.7%
CEO tenure9.3yrs
CEO ownership1.1%
Management average tenure8.1yrs
Board average tenure6.8yrs

Recent management updates

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07
Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Recent updates

Pliant Therapeutics: Strange Volatility

Feb 11

Pliant Therapeutics (NASDAQ:PLRX) Has Debt But No Earnings; Should You Worry?

Jan 02
Pliant Therapeutics (NASDAQ:PLRX) Has Debt But No Earnings; Should You Worry?

Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?

Sep 13
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?

Pliant Therapeutics: Good Data, But Will Need Watching

Sep 11

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07
Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Feb 27
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Jul 21
Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Mar 13
Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Sep 10
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics: Wait For A Better Price To Get In

Aug 20

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Aug 08

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28
Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22
We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29
Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07
We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Bernard Coulie's remuneration changed compared to Pliant Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$7mUS$641k

-US$210m

Sep 30 2024n/an/a

-US$202m

Jun 30 2024n/an/a

-US$185m

Mar 31 2024n/an/a

-US$171m

Dec 31 2023US$11mUS$610k

-US$161m

Sep 30 2023n/an/a

-US$155m

Jun 30 2023n/an/a

-US$144m

Mar 31 2023n/an/a

-US$133m

Dec 31 2022US$11mUS$587k

-US$123m

Sep 30 2022n/an/a

-US$113m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$103m

Dec 31 2021US$5mUS$556k

-US$97m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$2mUS$499k

-US$42m

Sep 30 2020n/an/a

US$18m

Jun 30 2020n/an/a

US$19m

Mar 31 2020n/an/a

US$20m

Dec 31 2019US$2mUS$428k

-US$7m

Compensation vs Market: Bernard's total compensation ($USD6.61M) is above average for companies of similar size in the US market ($USD682.63K).

Compensation vs Earnings: Bernard's compensation has been consistent with company performance over the past year.

CEO

Bernard Coulie (58 yo)

9.3yrs

Tenure

US$6,614,704

Compensation

Dr. Bernard Coulie, Ph D, M.D. M.B.A. is Independent Director of Septerna, Inc. from December 2023. He served as Independent Director at SQZ Biotechnologies Company since July 2021 until March 2024 and ser...

Leadership Team

NamePositionTenureCompensationOwnership
Bernard Coulie
Presidentno dataUS$6.61m1.15%
$ 1.0m
Keith Cummings
Chief Financial Officer6.4yrsUS$3.10m0.34%
$ 297.1k
Mike Ouimette
Chief Legal & Compliance Officer and Secretary4.6yrsUS$1.99m0.060%
$ 52.3k
Johannes Hull
Chief Business Officer9.2yrsUS$2.02m0.33%
$ 292.2k
Eric Lefebvre
Chief Medical Officer7yrsUS$2.62m0.24%
$ 210.2k
Rik Derynck
Scientific Founder & Member of Scientific Advisory Board10.3yrsno datano data
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Board10.3yrsno datano data
Bill DeGrado
Scientific Founder & Member of Scientific Advisory Board10.3yrsno datano data
Hal Chapman
Scientific Founder & Member of Scientific Advisory Board10.3yrsno datano data
Delphine Imbert
Chief Technical Officerless than a yearno datano data
Christopher Keenan
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Lily Cheung
Chief Human Resources Officer2.3yrsno data0.012%
$ 10.3k

8.1yrs

Average Tenure

50.5yo

Average Age

Experienced Management: PLRX's management team is seasoned and experienced (8.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bernard Coulie
President9.3yrsUS$6.61m1.15%
$ 1.0m
Rik Derynck
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Bill DeGrado
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Hal Chapman
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Gayle Crowell
Independent Director5.4yrsUS$287.60k0%
$ 0
Suzanne Bruhn
Independent Director8.8yrsUS$282.80k0.057%
$ 50.2k
John Curnutte
Independent Director7.8yrsUS$276.80k0.048%
$ 41.9k
Hoyoung Huh
Independent Chairman & Lead Director7.4yrsUS$304.64k0.16%
$ 142.7k
Steve Krognes
Independent Directorless than a yearUS$501.14k0%
$ 0
Darren Cline
Independent Director2.2yrsUS$279.53k0%
$ 0
Smital Shah
Independent Director6.2yrsUS$281.43k0%
$ 0

6.8yrs

Average Tenure

59yo

Average Age

Experienced Board: PLRX's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 02:52
End of Day Share Price 2025/05/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pliant Therapeutics, Inc. is covered by 18 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward NashCanaccord Genuity
Pete StavropoulosCantor Fitzgerald & Co.
David LebowitzCitigroup Inc